Loading...
•
Sep 30, 2023
STERIS Q2 2024 Earnings Report
STERIS's revenue increased by 12% and constant currency organic revenue increased by 8%.
Key Takeaways
STERIS announced financial results for the second quarter of fiscal year 2024, with revenue increasing by 12% to $1.34 billion and constant currency organic revenue increasing by 8%. The Healthcare segment continued to show momentum, offsetting macro challenges in other segments. The integration of the surgical instrumentation business purchased from BD is progressing as planned.
Second quarter revenue growth of 12% as reported and 8% constant currency organic.
As reported diluted earnings per share increased to $1.16; adjusted earnings increased to $2.03.
Fiscal 2024 outlook maintained.
Healthcare segment is anticipated to outperform original expectations for the fiscal year, offsetting macro challenges impacting demand in other segments.
Revenue by Segment
Forward Guidance
The company is confirming its outlook for fiscal 2024 of as reported revenue growth of 9-10% and constant currency organic revenue growth of 6-7%. Adjusted earnings per diluted share are anticipated to be in the range of $8.60 to $8.80. Free cash flow for fiscal 2024 is anticipated to be approximately $685 million.
Positive Outlook
- As reported revenue growth of 9-10%.
- Constant currency organic revenue growth of 6-7%.
- Adjusted earnings per diluted share are anticipated to be in the range of $8.60 to $8.80.
- Free cash flow for fiscal 2024 is anticipated to be approximately $685 million.
- Confirming outlook for fiscal 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...